Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (19704)	4/27/1998 5:37:00 PM
From: David L. Hachey	Read Replies (1) \| Respond to of 32384

Walter; SEPR may be a special case. In addition to their chiral separation technology, they are taking proven racemic drugs and isolating the active enantiomer and removing a potentially hazardous enantiomer. There are fewer obstacles in this path to drug development, but they still have to jump through the FDA hoops. Although LGND's technology is very promising, a much greater level of development is required. Also, there is some competition in the field which may be unpredictable to evaluate. I own a few thousand shares of LGND, so that should tell you which way I'm betting. Regards, ...Dave